The same event can reach both: a study opening is one line under its program in the brief, and one study’s change in the alerts.
The registry lists 3,336 studies for Arthritis, Rheumatoid across more than 10 countries. 445 are recruiting or about to start. 2,807 of them are mainly about Arthritis, Rheumatoid (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 2 narrower conditions too, such as Sjogren's Syndrome: 3,641 studies, 524 open.
ClinicalTrials.gov finds 3,814 studies for Arthritis, Rheumatoid.How that becomes 3,334 here
This page counts the studies the registry files under Arthritis, Rheumatoid, and those it files under no condition that list Arthritis, Rheumatoidthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count
3,814Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−56List Arthritis, Rheumatoid as a condition, but the registry did not file them under itMost often written as “Juvenile Rheumatoid Arthritis” (18), “Rheumatoid Arthritis of Knee” (8), and “Rheumatoid Arthritis Shoulder” (5). The registry filed them under other conditions only, most often Arthritis, Juvenile (23) and Arthritis (10).
−128Match it another way82 name it in the title, 12 in a keyword, and 34 by a synonym or other text the search reads.
3,334The count on this page44 of them list Arthritis, Rheumatoid in their own words; the registry filed them under no condition.
Every program with a company-led study here in the last two years, whatever its size: 73 programs from 50 companies, 49 with this as their studies’ main aim; 2 with a live phase 3 study; 12 primary completions in the next 12 months. Compare AbbVie, Bristol-Myers Squibb and AstraZeneca here →
Comparator & background therapies
What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.
“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.
The 2 in phase 3 with the nearest primary completion, of 73 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.
Primary completion in the next 12 months (12)
Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.
Dec 2026 est.TOLLB-001· Toll Biotech Co. Ltd. (Beijing) · Phase 2main aimNCT07408024 Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis — primary endpoint: Safety-AE/lab tests/PE/VS/ECG · 24 enrolled
31 Dec 2026 est.TLL-018· Hangzhou Highlightll Pharmaceutical Co., Ltd · Phase 3main aimNCT06887127 A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis — primary endpoint: Number of occurrences and Percentage of Participants with AEs and SAEs · 350 enrolled
Feb 2027 est.lutikizumab, ravagalimab· AbbVie · Phase 2main aimNCT06972446 A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis — primary endpoint: Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response · 180 enrolled
Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.
What is being tested here
Drugs under test in Arthritis, Rheumatoid studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
139studies finish main data collection within a year7 of them phase 3
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger. 15 (5%) take children under 18. 7 (2%) are for women only and 2 (1%) for men only; 36 (12%) take healthy volunteers.
Across all 3,336 studies, recruiting or not: 30% stop at 75 or younger and 13% at 65; 6% take children; 3% are for women only and 1% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Arthritis, Rheumatoid studies take
Of 158 phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 18 months of starting, counting those still running.
Start to primary completion
Every sponsor
Industry
Non-industry
Phase 1
16 mo5–32 · 148 studies
13 mo5–32 · 128 studies
—
Phase 1/2
22 mo12–26 · 29 studies
—
—
Phase 2
18 mo13–30 · 158 studies
17 mo13–24 · 116 studies
43 mo13–49 · 42 studies
Phase 3
26 mo17–40 · 148 studies
24 mo16–31 · 116 studies
—
Phase 4
42 mo25–74 · 104 studies
26 mo16–44 · 25 studies
49 mo30–92 · 79 studies
Interventional, no phase
27 mo13–51 · 348 studies
61 mo26–92 · 56 studies
24 mo12–39 · 292 studies
Observational
50 mo25–113 · 391 studies
60 mo32–113 · 155 studies
43 mo19–122 · 236 studies
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 18, 2026.